Company / Net Income
Mirum Pharmaceuticals, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$23.4M
FY2025
5-year range
-$163.4M / -$23.4M
FY2021-FY2025
Trend
+73.4%
vs FY2024
Sector context
#73 of 216
Health Care
What the data says
At -$23M, Mirum Pharmaceuticals, Inc.'s net income ranks #73 of 216 in the Health Care sector. Improved from -$163M to -$23M over the past 2 years.
Based on SEC 10-K filings.
-$23M in FY2025.
Improved from -$163M to -$23M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#73 of 216 in Health CareTop 34% of 216This company -$23.4M Sector average $454.1M
▼
-105.1% below sector average
Key checks
Key Insights
- In FY2025, net income increased 73.4% year-over-year.
- Ranks #73 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$23.4M | +73.4% |
| FY2024 | -$87.9M | +46.2% |
| FY2023 | -$163.4M | -94.6% |
| FY2022 | -$84.0M | +18.7% |
| FY2021 | -$103.3M | +0.0% |
| FY2020 | -$103.3M | -96.5% |
| FY2019 | -$52.6M | -202.9% |
| FY2018 | -$17.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026